𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cancer and Leukemia Group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas

✍ Scribed by A.W. Blackstock; M.A. Tempero; D. Niedwiecki; D.R. Hollis; R.J. Mayer; J.E. Tepper

Book ID
108434439
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
16 KB
Volume
51
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of etoposide and cis-diam
Phase II trial of etoposide and cis-diaminodichloro-platinum in patients with refractory and relapsed Hodgkin's disease: Cancer and leukemia group B (CALGB) study 8353
✍ Rybak, Mary Ellen ;McCarroll, Kathleen ;Kaplan, Richard J. ;Propert, Kathleen J. πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 394 KB

## Abstract A phase II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed Hodgkin's disease (HD) to assess the activity of the combination of etoposide and cis‐platin. Twenty‐seven patients were entered; 22 were evaluated for this report. Treatme

Phase II trial of ifosfamide and mesna i
Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8552
✍ Case, Delvyn C. ;Anderson, James ;Ervin, Thomas J. ;Gottlieb, Arlan πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 481 KB

Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and

Phase II trial of ifosfamide and mesna i
Phase II trial of ifosfamide and mesna in previously treated patients with non-hodgkin's lymphoma: Cancer and leukemia group b study 8552
✍ Delvyn C. Case JR; James Anderson; Thomas J. Ervin; Arlan Gottlieb πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 522 KB

## Abstract Ifosfamide (1Β·25 g/m^2^ intravenously/day Γ— 5) with mesna (20 per cent of the ifosfamide dose Γ— six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non‐Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29 per cent response rat